These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34266584)

  • 1. Phosphodiesterase-5 Inhibitors in Men With Stable Coronary Artery Disease.
    Wen Z; Feng Y; Jiang L
    J Am Coll Cardiol; 2021 Jul; 78(3):294-295. PubMed ID: 34266584
    [No Abstract]   [Full Text] [Related]  

  • 2. Phosphodiesterase-5 Inhibitors and Survival in Men With Coronary Artery Disease.
    Maas R; Rodionov RN
    J Am Coll Cardiol; 2021 Mar; 77(12):1551-1553. PubMed ID: 33766261
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil with Survival in Men with Coronary Artery Disease.
    Reddy R; Diaz P; Ramasamy R
    Eur Urol; 2022 Jan; 81(1):120-121. PubMed ID: 34772548
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentaries on Jackson et al. "Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction".
    Kloner RA; Montorsi P; DeBusk RF
    J Sex Med; 2005 Sep; 2(5):740-2; author reply 742. PubMed ID: 16422835
    [No Abstract]   [Full Text] [Related]  

  • 5. Erectile dysfunction in the cardiac patient.
    Kloner RA
    Curr Urol Rep; 2003 Dec; 4(6):466-71. PubMed ID: 14622500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erectile dysfunction and coronary atherothrombosis in diabetic patients: pathophysiology, clinical features and treatment.
    Gazzaruso C
    Expert Rev Cardiovasc Ther; 2006 Mar; 4(2):173-80. PubMed ID: 16509813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease.
    Thadani U; Smith W; Nash S; Bittar N; Glasser S; Narayan P; Stein RA; Larkin S; Mazzu A; Tota R; Pomerantz K; Sundaresan P
    J Am Coll Cardiol; 2002 Dec; 40(11):2006-12. PubMed ID: 12475462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase-5 Inhibitors: Are the Panacea for Several Urologic Diseases?
    Giusti G; Proietti S
    J Endourol; 2017 Aug; 31(8):814. PubMed ID: 28605937
    [No Abstract]   [Full Text] [Related]  

  • 9. The unexpected evolution of basic science studies about cyclic nucleotide action into a treatment for erectile dysfunction.
    Corbin J
    J Biol Chem; 2015 Jan; 290(3):1374-88. PubMed ID: 25505249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase-5 inhibitors and their use in the treatment of urological conditions.
    Petros P
    Curr Pharm Des; 2009; 15(30):3463. PubMed ID: 19860691
    [No Abstract]   [Full Text] [Related]  

  • 11. Do phosphodiesterase-5 inhibitors have a cardioprotective effect?
    Facio Junior FN; Querichelli AFA; Santos BDR; Arruda GJF; Spessoto LCF
    Rev Assoc Med Bras (1992); 2020 Nov; 66(11):1464-1465. PubMed ID: 33295389
    [No Abstract]   [Full Text] [Related]  

  • 12. Erectile dysfunction therapy in special populations and applications: coronary artery disease.
    DeBusk RF
    Am J Cardiol; 2005 Dec; 96(12B):62M-66M. PubMed ID: 16387570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Optimization of the use of phosphodiesterase-5 inhibitors].
    Pushkar' DIu; Segal AS
    Urologiia; 2012; (4):79-80, 82. PubMed ID: 23116030
    [No Abstract]   [Full Text] [Related]  

  • 14. [Erectile dysfunction and phosphodiesterase type 5 inhibitors].
    Roumeguère T; Sternon J; Schulman CC
    Rev Med Brux; 2003 Jun; 24(3):169-75. PubMed ID: 12891884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erectile dysfunction: Too much ROCK - erection block.
    Thoma C
    Nat Rev Urol; 2017 Jan; 14(1):6. PubMed ID: 27824350
    [No Abstract]   [Full Text] [Related]  

  • 16. Can low intensity shockwave therapy match the efficacy of phosphodiesterase-5 inhibitors for erectile dysfunction treatment? A pooled data analysis from two randomized clinical trials.
    Mykoniatis I; Kalyvianakis D; Kapoteli P; Zilotis F; Fournaraki A; Poulios E; Hatzichristou D
    Int J Impot Res; 2021 Apr; 33(3):383-385. PubMed ID: 32203424
    [No Abstract]   [Full Text] [Related]  

  • 17. Erectile dysfunction after radical prostatectomy: treatment options.
    Glina S
    Drugs Aging; 2011 Apr; 28(4):257-66. PubMed ID: 21428461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Montorsi F; Briganti A; Salonia A; Montorsi P; Rigatti P
    Curr Opin Urol; 2004 Nov; 14(6):357-9. PubMed ID: 15626879
    [No Abstract]   [Full Text] [Related]  

  • 19. PDE5 inhibitors and their applications.
    Giovannoni MP; Vergelli C; Graziano A; Dal Piaz V
    Curr Med Chem; 2010; 17(24):2564-87. PubMed ID: 20491634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of the association between erectile dysfunction and cardiovascular disease.
    Gandaglia G; Briganti A; Jackson G; Kloner RA; Montorsi F; Montorsi P; Vlachopoulos C
    Eur Urol; 2014 May; 65(5):968-78. PubMed ID: 24011423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.